References
- Sievers BL, Cheng MTK, Csiba K, Meng B, Gupta RK. SARS-CoV-2 and innate immunity: the good, the bad, and the “goldilocks”. Cell Mol Immunol. 2024;21(2):171-83.
- Wang X, Lu L, Jiang S. SARS-CoV-2 evolution from the BA.2.86 to JN.1 variants: unexpected consequences. Trends in Immunology. 2024;45(2):81-4.
- Steiner S, Kratzel A, Barut GT, Lang RM, Aguiar Moreira E, Thomann L, et al. SARS-CoV-2 biology and host interactions. Nat Rev Microbiol. 2024;22(4):206-25.
- Lam ICH, Zhang R, Man KKC, Wong CKH, Chui CSL, Lai FTT, et al. Persistence in risk and effect of COVID-19 vaccination on long-term health consequences after SARS-CoV-2 infection. Nat Commun. 2024;15(1):1716.
- Meinhardt J, Streit S, Dittmayer C, Manitius R, Radbruch H, Heppner FL. The neurobiology of SARS-CoV-2 infection. Nat Rev Neurosci. 2024;25(1):30-42.
- Partiot E, Hirschler A, Colomb S, Lutz W, Claeys T, Delalande F, et al. Brain exposure to SARS-CoV-2 virions perturbs synaptic homeostasis. Nat Microbiol. 2024;9(5):1189-206.
- Xu C, Hou P, Li X, Xiao M, Zhang Z, Li Z, et al. Comprehensive understanding of glioblastoma molecular phenotypes: classification, characteristics, and transition. Cancer Biol Med. 2024;21(5):363-81.
- Richter V, Ernemann U, Bender B. Novel imaging approaches for glioma classification in the Era of the World Health Organization 2021 update: A scoping review. Cancers. 2024;16(10):1792.
- Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro Oncol. 2021;23(8):1231-51.
- Dong J, Wang S, Xie H, Mou Y, Zhu H, Peng Y, et al. COVID-19 hospitalization increases the risk of developing glioblastoma: a bidirectional Mendelian-randomization study. Front Oncol. 2023;13:1185466.
- Diajhete R, Cisse Y, Ba M, Sall A, Ba D, Coumé M. Glioblastoma and COVID-19 in an elderly patient about a case: Review of the literature. Int J Neurol Res. 2024;6(1):01-4.
- Hu H, Wang C, Tao R, Liu B, Peng D, Chen Y, et al. Evidences of neurological injury caused by COVID-19 from glioma tissues and glioma organoids. CNS Neurosci Ther. 2024;30(6):e14822.
- Mohile NA, Blakeley JO, Gatson NTN, Hottinger AF, Lassman AB, Ney DE, et al. Urgent considerations for the neuro-oncologic treatment of patients with gliomas during the COVID-19 pandemic. Neuro Oncol. 2020;22(7):912-7.
- Yalamarty SSK, Filipczak N, Li X, Subhan MA, Parveen F, Ataide JA, et al. Mechanisms of resistance and current treatment options for Glioblastoma Multiforme (GBM). Cancers. 2023;15(7):2116.
- Bikfalvi A, Costa CA da, Avril T, Barnier JV, Bauchet L, Brisson L, et al. Challenges in glioblastoma research: focus on the tumor microenvironment. Trends Cancer. 2023;9(1):9-27.
- Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, et al. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro-Oncology. 2019;21(Supplement_5):v1-100.
- Gatson NTN, Barnholtz-Sloan J, Drappatz J, Henriksson R, Hottinger AF, Hinoul P, et al. Tumor treating fields for glioblastoma therapy during the COVID-19 pandemic. Front Oncol. 2021;11:679702.
- Bhola S, Trisal J, Thakur V, Kaur P, Kulshrestha S, Bhatia SK, et al. Neurological toll of COVID-19. Neurol Sci. 2022;43(4):2171-86.
- Belopasov VV, Yachou Y, Samoilova EM, Baklaushev VP. The nervous system damage in COVID-19. J Clin Pract. 2020;11(2):60-80.
- Granholm AC. Long-term effects of SARS-CoV-2 in the brain: Clinical consequences and molecular mechanisms. J Clin Med. 2023;12(9):3190.
- Zhang L, Zhou L, Bao L, Liu J, Zhu H, Lv Q, et al. SARS-CoV-2 crosses the blood-brain barrier accompanied with basement membrane disruption without tight junctions alteration. Signal Transduct Target Ther. 2021;6(1):337.
- Smirnova OA, Ivanova ON, Fedyakina IT, Yusubalieva GM, Baklaushev VP, Yanvarev DV, et al. SARS-CoV-2 establishes a productive infection in hepatoma and glioblastoma multiforme cell lines. Cancers. 2023;15(3):632.
- Kyriakopoulos AM, Nigh G, McCullough PA, Seneff S. Mitogen Activated Protein Kinase (MAPK) activation, p53, and autophagy inhibition characterize the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike protein induced neurotoxicity. Cureus. 14(12):e32361.
- Gregory TA, Knight SR, Aaroe AE, Highsmith KN, Janatpour ZC, O’Brien BJ, et al. Accelerated tumor progression after COVID-19 infection in patients with glioblastoma: A retrospective case – control study. Neurooncol Pract. 2024;11(4):475-83.
- Lei J, Liu Y, Xie T, Yao G, Wang G, Diao B, et al. Evidence for residual SARS-CoV-2 in glioblastoma tissue of a convalescent patient. Neuroreport. 2021;32(9):771-5.
- Suarez-Meade P, Watanabe F, Ruiz-Garcia H, Rafferty SB, Moniz-Garcia D, Schiapparelli PV, et al. SARS-CoV2 entry factors are expressed in primary human glioblastoma and recapitulated in cerebral organoid models. J Neurooncol. 2023;161(1):67-76.
- Keyhanian K, Umeton RP, Mohit B, Davoudi V, Hajighasemi F, Ghasemi M. SARS-CoV-2 and nervous system: From pathogenesis to clinical manifestation. J Neuroimmunol. 2021;350:577436.
- Crunf li F, Carregari VC, Veras FP, Silva LS, Nogueira MH, Antunes ASLM, et al. Morphological, cellular, and molecular basis of brain infection in COVID-19 patients. Proc Natl Acad Sci. 2022;119(35):e2200960119.
- Hikmet F, Méar L, Edvinsson Å, Micke P, Uhlén M, Lindskog C. The protein expression profile of ACE2 in human tissues. Mol Syst Biol. 2020;16(7):e9610.
- Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: A multicenter study during the COVID-19 outbreak. Cancer Discovery. 2020;10(6):783-91.
- Li Z, Wei Y, Zhu G, Wang M, Zhang L. Cancers and COVID-19 risk: A mendelian randomization study. Cancers (Basel). 2022;14(9):2086.
- Jiang Y, Wu Q, Song P, You C. The variation of SARS-CoV-2 and advanced research on current vaccines. Front Med (Lausanne). 2021;8:806641.
- Kannan S, Shaik Syed Ali P, Sheeza A. Omicron (B.1.1.529) – variant of concern –molecular profile and epidemiology: a mini review. Eur Rev Med Pharmacol Sci. 2021;25(24):8019-22.
- Boehm E, Kronig I, Neher RA, Eckerle I, Vetter P, Kaiser L. Novel SARS-CoV-2 variants: the pandemics within the pandemic. Clin Microbiol Infect. 2021;27(8):1109-17.
- Greenberger LM, Saltzman LA, Senefeld JW, Johnson PW, DeGennaro LJ, Nichols GL. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. Cancer Cell. 2021;39(8):1031-3.
- Thakkar A, Pradhan K, Jindal S, Cui Z, Rockwell B, Shah AP, et al. Patterns of seroconversion for SARS-CoV2-IgG in patients with malignant disease and association with anticancer therapy. Nat Cancer. 2021;2(4):392-9.
- Sahin U, Muik A, Vogler I, Derhovanessian E, Kranz LM, Vormehr M, et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature. 2021;595(7868):572-7.
- Ehmsen S, Asmussen A, Jeppesen SS, Nilsson AC, Østerlev S, Vestergaard H, et al. Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer. Cancer Cell. 2021;39(8):1034-6.
- Bange EM, Han NA, Wileyto P, Kim JY, Gouma S, Robinson J, et al. CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat Med. 2021;27(7):1280-9.
- Mairhofer M, Kausche L, Kaltenbrunner S, Ghanem R, Stegemann M, Klein K, et al. Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancer. Cancer Cell. 2021;39(9):1171-2.
- Lo Sasso B, Giglio RV, Vidali M, Scazzone C, Bivona G, Gambino CM, et al. Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine. Diagnostics. 2021; 11(7):1135.